Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Nisman

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The Israel Medical Association Journal : IMAJ|May 13, 2009
Extreme high levels of CA19-9 associated with adenocarcinoma of the lungYakir Rottenberg, Benjamin Nisman, Tamar Peretz
Expert Review of Anticancer Therapy|June 18, 2010
Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance?Vladimir Yutkin, Benjamin Nisman, Dov Pode
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancerVivian Barak, Stefan Holdenrieder, Benjamin Nisman, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 13, 2005
The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancerBenjamin Nisman, Norman Heching, Haim Biran, et al.
Cancer|July 13, 2002
Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinomaBenjamin Nisman, Vivian Barak, Amos Shapiro, et al.
Anticancer Research|October 23, 2009
The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot studyBenjamin Nisman, Vladimir Yutkin, Tamar Peretz, et al.
Anticancer Research|December 25, 2009
The diagnostic and prognostic value of ProGRP in lung cancerBenjamin Nisman, Haim Biran, Nili Ramu, et al.
Neoplasia (New York, N.Y.)|February 20, 2008
Clinical significance of urine heparanase in bladder cancer progressionItay Shafat, Dov Pode, Tamar Peretz, et al.
Biochemical and Biophysical Research Communications|February 7, 2006
An ELISA method for the detection and quantification of human heparanaseItay Shafat, Eyal Zcharia, Benjamin Nisman, et al.
Anticancer Research|December 26, 2012
The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancerBenjamin Nisman, Ofra Maimon, Tanir Allweis, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The Israel Medical Association Journal : IMAJ|May 13, 2009
Extreme high levels of CA19-9 associated with adenocarcinoma of the lungYakir Rottenberg, Benjamin Nisman, Tamar Peretz
Expert Review of Anticancer Therapy|June 18, 2010
Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance?Vladimir Yutkin, Benjamin Nisman, Dov Pode
Cancer Biomarkers : Section a of Disease Markers|July 28, 2010
Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancerVivian Barak, Stefan Holdenrieder, Benjamin Nisman, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 13, 2005
The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancerBenjamin Nisman, Norman Heching, Haim Biran, et al.
Cancer|July 13, 2002
Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinomaBenjamin Nisman, Vivian Barak, Amos Shapiro, et al.
Anticancer Research|October 23, 2009
The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: a pilot studyBenjamin Nisman, Vladimir Yutkin, Tamar Peretz, et al.
Anticancer Research|December 25, 2009
The diagnostic and prognostic value of ProGRP in lung cancerBenjamin Nisman, Haim Biran, Nili Ramu, et al.
Neoplasia (New York, N.Y.)|February 20, 2008
Clinical significance of urine heparanase in bladder cancer progressionItay Shafat, Dov Pode, Tamar Peretz, et al.
Biochemical and Biophysical Research Communications|February 7, 2006
An ELISA method for the detection and quantification of human heparanaseItay Shafat, Eyal Zcharia, Benjamin Nisman, et al.
Anticancer Research|December 26, 2012
The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancerBenjamin Nisman, Ofra Maimon, Tanir Allweis, et al.
Pageof 3